Objective： To evaluate the long-term efficacy and safety of pamidronate disodium in patients with bone lesions secondary to advanced breast carcinoma. Methods： A retrospective chart review was conducted of 62 patie...Objective： To evaluate the long-term efficacy and safety of pamidronate disodium in patients with bone lesions secondary to advanced breast carcinoma. Methods： A retrospective chart review was conducted of 62 patients receiving intravenous pamidronate disodium for metastatic breast cancer. The proportion of patients experiencing at least one skeletal related event （SRE） after 12 months of therapy was determined. Results： The proportion of patients who had an SRE was 29.00% （18 individuals） and the median time to first event was greater than 350 days. Radiotherapy（ll individuals）and pathologic fracture（6 individuals）were the most frequent type of SRE, while cord compression（1 individuals） and hypercalcaemia（0 individuals） were rare. A total of 37 individuals had transient hypocalcaemia without any clinical symptom. No significant creatinine abnormalities were encountered. There were no clinically relevant changes of calcium ,phosphate and creatinine before and after therapy. Conclusion： Long-term treatment with pamidronate disodium significantly reduces and delays skeletal morbidity from osteolytic metastases . Prolonged therapy was well tolerated. This study suggests that the rate of clinically relevant SREs is substantially lower than the event rate observed in phase llI clinical trials.展开更多
OBJECTIVE To evaluate the therapeuticeffect and potential adverse ef- fects of sodium ibandronate(SI)in patients with malignant tumor ostealgia. METHODS Patients were randomly classified into two groups.Group A(SI)of...OBJECTIVE To evaluate the therapeuticeffect and potential adverse ef- fects of sodium ibandronate(SI)in patients with malignant tumor ostealgia. METHODS Patients were randomly classified into two groups.Group A(SI)of 68 patients who received 4 mg SI i.v.,and 73 patients in Group B (pamidronate disodium[PD])who received 60 mg PD i.v.A randomized, double-blind method,with PD as a positive drug control,was used to assess changes in bone pain and adverse effects over a three-week period. RESULTS A total of 141 patients were enrol ed in the study,with 136 cases of appraisable efficacy.The effective rate was 72.3%(47/65)in Group A,and 63.4%(45/71)in Group B.There was no significant difference in ef- ficacy or adverse effects between the 2 groups. CONCLUSION The SI injection,with a pronounced effect,can relieve bone pain caused by osseous metastasis from a malignant tumor.The cura- tive and adverse effects were similar compared to PD.展开更多
文摘Objective： To evaluate the long-term efficacy and safety of pamidronate disodium in patients with bone lesions secondary to advanced breast carcinoma. Methods： A retrospective chart review was conducted of 62 patients receiving intravenous pamidronate disodium for metastatic breast cancer. The proportion of patients experiencing at least one skeletal related event （SRE） after 12 months of therapy was determined. Results： The proportion of patients who had an SRE was 29.00% （18 individuals） and the median time to first event was greater than 350 days. Radiotherapy（ll individuals）and pathologic fracture（6 individuals）were the most frequent type of SRE, while cord compression（1 individuals） and hypercalcaemia（0 individuals） were rare. A total of 37 individuals had transient hypocalcaemia without any clinical symptom. No significant creatinine abnormalities were encountered. There were no clinically relevant changes of calcium ,phosphate and creatinine before and after therapy. Conclusion： Long-term treatment with pamidronate disodium significantly reduces and delays skeletal morbidity from osteolytic metastases . Prolonged therapy was well tolerated. This study suggests that the rate of clinically relevant SREs is substantially lower than the event rate observed in phase llI clinical trials.
文摘OBJECTIVE To evaluate the therapeuticeffect and potential adverse ef- fects of sodium ibandronate(SI)in patients with malignant tumor ostealgia. METHODS Patients were randomly classified into two groups.Group A(SI)of 68 patients who received 4 mg SI i.v.,and 73 patients in Group B (pamidronate disodium[PD])who received 60 mg PD i.v.A randomized, double-blind method,with PD as a positive drug control,was used to assess changes in bone pain and adverse effects over a three-week period. RESULTS A total of 141 patients were enrol ed in the study,with 136 cases of appraisable efficacy.The effective rate was 72.3%(47/65)in Group A,and 63.4%(45/71)in Group B.There was no significant difference in ef- ficacy or adverse effects between the 2 groups. CONCLUSION The SI injection,with a pronounced effect,can relieve bone pain caused by osseous metastasis from a malignant tumor.The cura- tive and adverse effects were similar compared to PD.
